Literature DB >> 15038160

Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology.

Xiang Ling1, Fengzhi Li.   

Abstract

Silencing of mammalian gene expression by RNA interference (RNAi) technology can be achieved using small interfering RNA (siRNA) or short hairpin RNA (shRNA). However, the relative effectiveness of these two approaches is not known. It is also not clear whether gene-specific shRNA transcribed from an RNA polymerase II (Pol II)-directed promoter in a fusion form can disrupt the targeted gene expression. Here, we report that using both luciferase and antiapoptotic survivin genes as targets, both siRNA and shRNA approaches significantly silenced the targeted gene expression in cancer cells. We further demonstrated that shRNAs transcribed from an RNA Pol II-mediated promoter in a green fluorescent protein (GFP) fusion form at the 3'-untranslated region silenced luciferase and survivin expression as well, suggesting that the extra RNA sequence outside of the shRNA hairpin does not disrupt shRNA function. We also showed that silencing of survivin expression selectively induces apoptosis in transfected cells. Together, we have validated multiple approaches of RNAi technology using both survivin and luciferase genes as targets and demonstrated for the first time that GFP-shRNAs transcribed from an RNA Pol II-mediated promoter could mediate gene silencing, which may lead to new directions for the application of RNAi technology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15038160     DOI: 10.2144/04363RR01

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  30 in total

1.  Optimization and apoptosis induction by RNAi with UTMD technology in vitro.

Authors:  Zhi-Yi Chen; Kun Liang; Xiu-Jie Sheng; Bing Si-Tu; Xiao-Fang Sun; Jian-Qiao Liu; Ri-Xiang Qiu; Hua Zhang; Yue-Wei Li; Xin-Xin Zhou; Jiang-Xiu Yu
Journal:  Oncol Lett       Date:  2012-02-15       Impact factor: 2.967

2.  Survivin and escaping in therapy-induced cellular senescence.

Authors:  Qin Wang; Peter C Wu; Rachel S Roberson; Belinda V Luk; Iana Ivanova; Elizabeth Chu; Daniel Y Wu
Journal:  Int J Cancer       Date:  2010-05-25       Impact factor: 7.396

3.  Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity.

Authors:  Jianguo Wu; Xiang Ling; Dalin Pan; Pasha Apontes; Lei Song; Ping Liang; Dario C Altieri; Terry Beerman; Fengzhi Li
Journal:  J Biol Chem       Date:  2005-01-05       Impact factor: 5.157

4.  Effects of shRNA targeting survivin on apoptosis of human retinoblastoma cell line Hxo-rb44 in vitro.

Authors:  Guojun Wang; Yanhua Hu; Pengcheng Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

5.  Vascular smooth muscle-specific knockdown of the noncardiac form of the L-type calcium channel by microRNA-based short hairpin RNA as a potential antihypertensive therapy.

Authors:  Sung W Rhee; Joseph R Stimers; Wenze Wang; Li Pang
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

6.  Sanguinarine suppresses prostate tumor growth and inhibits survivin expression.

Authors:  Meng Sun; Wei Lou; Jae Yeon Chun; Daniel S Cho; Nagalakshmi Nadiminty; Christopher P Evans; Jun Chen; Jiao Yue; Qinghua Zhou; Allen C Gao
Journal:  Genes Cancer       Date:  2010-03

7.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.

Authors:  Jae Yeon Chun; Yan Hu; Elaine Pinder; Jianguo Wu; Fengzhi Li; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

8.  Novel ultrasound-targeted microbubble destruction mediated short hairpin RNA plasmid transfection targeting survivin inhibits gene expression and induces apoptosis of HeLa cells.

Authors:  Zhiyi Chen; Kun Liang; Mingxing Xie; Xinfang Wang; Qing Lü; Jing Zhang
Journal:  Mol Biol Rep       Date:  2008-11-09       Impact factor: 2.316

9.  Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin.

Authors:  Xiang Ling; Xiang He; Pasha Apontes; Felicia Cao; Rami G Azrak; Fengzhi Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

10.  Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.

Authors:  Xiang Ling; Diane Calinski; Asher A Chanan-Khan; Muxiang Zhou; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.